DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|RYLOCK|%tLOCK|s<#wtM

DSM-Firmenich Earnings: Solid Organic Sales Growth; Guidance Increased After One-Off Vitamins Boon

DSM-Firmenich reported solid third-quarter earnings and upgraded the 2024 adjusted EBITDA guidance by 5% to EUR 2.1 billion, citing a one-off tailwind in the vitamins market.

Sponsor Center